NASDAQ:KURA Kura Oncology Q3 2026 Earnings Date & Estimates $7.61 -2.27 (-22.98%) Closing price 11/4/2026 04:00 PM EasternExtended Trading$7.66 +0.05 (+0.64%) As of 08:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Kura Oncology is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 10, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Kura Oncology in Q3 2026Kura Oncology is expected to post earnings of -$0.83 per share on revenue of $24.94 million. In the same quarter a year earlier Kura Oncology reported -$0.85 per share on revenue of $20.75 million. Kura Oncology last reported on August 12, 2026, posting -$0.77 per share and beating the -$0.8773 consensus estimate. Kura Oncology has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.83Expected Revenue$24.94 millionPrior-Year EPS-$0.85Prior-Year Revenue$20.75 millionExpected Revenue Growth+20.2%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.77 (Beat by +$0.1073)Last Quarter Revenue$20.87 millionEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Kura Oncology Q3 2026 Earnings FAQ When does Kura Oncology report Q3 2026 earnings? Kura Oncology (NASDAQ:KURA) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Kura Oncology's Q3 2026 earnings call? Kura Oncology's Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Kura Oncology? Analysts expect Kura Oncology to post earnings of -$0.83 per share for Q3 2026. How much revenue is Kura Oncology expected to report? The consensus revenue estimate for Kura Oncology is $24.94 million for Q3 2026. Kura Oncology Earnings HeadlinesKura Oncology, Inc. (NASDAQ:KURA) Stock Rated "Moderate Buy" by Wall Street BrokeragesNovember 5 at 2:29 AM | americanbankingnews.comKura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026November 4 at 9:02 AM | globenewswire.comThis little-known fund tracks gold and pays out weeklyA little-known $15 fund tied to gold could pay you cash every Friday, no mining stock required. In one recent month, those payments added up to $1,127, without the risks of management decisions or rising mining costs.November 5 at 1:00 AM | Investors Alley (Ad)Kura Oncology to Report Third Quarter Financial Results on November 10November 3 at 6:58 AM | globenewswire.comKura Oncology (KURA) Set to Announce Quarterly Earnings on TuesdayNovember 2 at 2:26 AM | americanbankingnews.comBank of America Securities Remains a Buy on Kura Oncology (KURA)October 31, 2026 | theglobeandmail.comSee More Kura Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kura Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kura Oncology and other key companies, straight to your email. Email Address About Kura OncologyKura Oncology (NASDAQ:KURA) (NASDAQ: KURA) is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target genetic and molecular drivers of malignancies, with the goal of developing therapies for patients with limited treatment options. Kura’s lead product candidate has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia (AML), including AML associated with NPM1 mutations and KMT2A rearrangements. The company has also pursued additional targeted oncology programs, including drug candidates designed to inhibit pathways involved in tumor growth and resistance to treatment. Founded in 2014 and headquartered in San Diego, California, Kura has conducted clinical development activities in the United States and internationally through research collaborations and clinical-trial networks. The company has historically been led by Troy Wilson, Ph.D., who served as president and chief executive officer. Its operations have primarily centered on research, clinical development and regulatory advancement rather than commercial pharmaceutical sales.View Kura Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keurig Dr Pepper's Beverage Growth Raises a Tough Question About Its Coffee SplitAmazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushBloom Energy: The Off-Grid Answer to AI's Power DrainWhy ExxonMobil and Chevron Reminded Investors to Keep it Simple Upcoming Earnings Enbridge (11/6/2026)Brookfield Asset Management (11/6/2026)Humana (11/6/2026)Moderna (11/6/2026)Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
